Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Puma Biotechnology, Inc.

< Previous 1 2 Next >
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Third Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.